


AMENDMENTS TO THE CLAIMS

LISTING OF CLAIMS:

Please amend the claims presently on file as follows:

Claim 1. (previously presented) An hydrophobic GRF analog of formula A:



wherein; the GRF peptide is a peptide of formula B;

A1-A2-Asp-Ala-Ile-Phe-Thr-A8-Ser-Tyr-Arg-Lys-A13-Leu-A15-Gln-Leu-A-18-Ala-Arg-Lys-Leu-Leu-A24-A25-Ile-A27-A28-Arg-A30-R₀ (B)

wherein,

A1 is Tyr or His;

A2 is Val or Ala;

A8 is Asn or Ser;

A13 is Val or Ile;

A15 is Ala or Gly;

A18 is Ser or Tyr;

A24 is Gln or His;

A25 is Asp or Glu;

A27 is Met, Ile or Nle;

A28 is Ser or Asn;

A30 is a bond or any amino acid sequence of 1 up to 15 residues;

R₀ is NH₂ or NH-(CH₂)_n-CONH₂, with **n**=1 to 12 and

X is a hydrophobic tail anchored via an amide bond to the N-terminus of the peptide and said hydrophobic tail defining a backbone of 5 to 7 atoms;


wherein said backbone can be substituted by C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or

C₆₋₁₂ aryl and said backbone comprises at least one rigidifying moiety


connected to at least two atoms of the backbone;

said moiety selected from the group consisting of triple bond, saturated or unsaturated C₃₋₉ cycloalkyl, and C₆₋₁₂ aryl.


Claim 2. (currently amended) The hydrophobic GRF analog of claim 1, wherein **X** is selected from the group consisting of:




1 (R=H or CH₃ or CH₂CH₃)




2 (R=H or CH₃ or CH₂CH₃)
cis or trans, both as racemic mixtures
or pure enantiomeric pairs




3 (R=H or CH₃ or CH₂CH₃)
cis or trans, both as racemic mixtures
or pure enantiomeric pairs



4 (R=H or CH₃ or CH₂CH₃)
cis or trans, (when R ≠ H)
both as racemic mixtures
or pure enantiomeric pairs




5 (R=H or CH₃ or CH₂CH₃)
cis or trans, both as racemic mixtures
or pure enantiomeric pairs



6 ($\text{R}=\text{H}$ or CH_3 or CH_2CH_3)


cis or trans, (when $\text{R} \neq \text{H}$)

both as racemic mixtures
or pure enantiomeric pairs



7 ($\text{R}=\text{H}$ or CH_3 or CH_2CH_3)


cis or trans, both as racemic mixtures
or pure enantiomeric pairs



8 ($\text{R}=\text{H}$ or CH_3 or CH_2CH_3)

cis or trans, (when $\text{R} \neq \text{H}$)


both as racemic mixtures
or pure enantiomeric pairs




9 ($\text{R}=\text{H}$ or CH_3 or CH_2CH_3)

cis or trans, (when $\text{R} \neq \text{H}$)


both as racemic mixtures
or pure enantiomeric pairs




10 (R=H or CH₃ or CH₂CH₃)



11 (R=H or CH₃ or CH₂CH₃)



12 (R=H or CH₃ or CH₂CH₃)



13

Claim 3. (Canceled)

Claim 4. (previously presented) A method for increasing the level of growth hormone in a patient, the method comprising administering to said patient an effective amount of a GRF analog as claimed in claim 1.

Claim 5. (previously presented) A method for the diagnosis of growth hormone deficiency in a patient, the method comprising administering to said patient an effective amount of a GRF analog as claimed in claim 1 and measuring growth hormone response.

Claim 6. (currently amended) A method for the treatment of pituitary ~~dwarfism~~ dwarfism or growth retardation in a patient, the method comprising administering to said patient an effective amount of a GRF analog as claimed in claim 1.

Claim 7. (previously presented) A method for the treatment of wound or bone healing in a patient, the method comprising administering to said patient an effective amount of a GRF analog as claimed in claim 1.

Claim 8. (previously presented) A method for the treatment of osteoporosis in a patient, the method comprising administering to said patient an effective amount of a GRF analog as claimed in claim 1.

Claim 9. (previously presented) A method for improving protein anabolism in a human or an animal, the method comprising administering to said human or animal an effective amount of a GRF analog as claimed in claim 1.

Claim 10. (previously presented) A method for inducing a lipolytic effect in a human or an animal inflicted with clinical obesity, the method comprising administering to the human or animal an effective amount of a GRF analog as claimed in claim 1.

Claim 11. (previously presented) A method for the overall upgrading of somatroph function in human or animal, the method comprising administering to said patient an effective amount of a GRF analog as claimed in claim 1.

Claim 12. (new) A pharmaceutical formulation for inducing growth hormone release comprising: a GRF analog as claimed in claim 1, as an active ingredient, and a pharmaceutically acceptable carrier, excipient, or diluent in association with said GRF analog.